A Novel Polymer Nanoparticle Polydimethyl Diallyl Ammonium Chloride as An Adjuvant Enhances the Immune Response of SARS-CoV-2 Subunit Vaccine
© 2024 Wiley-VCH GmbH..
The Coronavirus Disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has a significant impact on global health and the economy. It has underscored the urgent need for a stable, easily produced and effective vaccine. This study presents a novel approach using SARS-CoV-2 spike (S) protein-conjugated nanoparticles (NPs) in combination with cyclic GMP-AMP (cGAMP) (S-NPs-cGAMP) as a subunit vaccine. When mice are immunized, the antiserum of S-NPs-cGAMP group exhibits a 16-fold increase in neutralizing activity against a pseudovirus, compared to S protein group. Additionally, S-NPs-cGAMP induces even higher levels of neutralizing antibodies. Remarkably, the vaccine also triggers a robust humoral immune response, as evidenced by a notable elevation in virus-specific IgG and IgM antibodies. Furthermore, after 42 days of immunization, there is an observed increase in specific immune cell populations in the spleen. CD3+ CD4+ and CD3+ CD8+ T lymphocytes, as well as B220+ CD19+ and CD3- CD49b+ NK lymphocytes, show an upward trend, indicating a positive cellular immune response. Moreover, the S-NPs-cGAMP demonstrates promising results against the Delta strain and exhibits good cross-neutralization potential against other variants. These findings suggest that pDMDAAC NPs is potential adjuvant and could serve as a versatile platform for future vaccine development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Advanced healthcare materials - (2024) vom: 04. März, Seite e2304575 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ren, Lili [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvant |
|---|
| Anmerkungen: |
Date Revised 10.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/adhm.202304575 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369265327 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369265327 | ||
| 003 | DE-627 | ||
| 005 | 20240311232520.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/adhm.202304575 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM369265327 | ||
| 035 | |a (NLM)38436662 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ren, Lili |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Novel Polymer Nanoparticle Polydimethyl Diallyl Ammonium Chloride as An Adjuvant Enhances the Immune Response of SARS-CoV-2 Subunit Vaccine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 Wiley-VCH GmbH. | ||
| 520 | |a The Coronavirus Disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has a significant impact on global health and the economy. It has underscored the urgent need for a stable, easily produced and effective vaccine. This study presents a novel approach using SARS-CoV-2 spike (S) protein-conjugated nanoparticles (NPs) in combination with cyclic GMP-AMP (cGAMP) (S-NPs-cGAMP) as a subunit vaccine. When mice are immunized, the antiserum of S-NPs-cGAMP group exhibits a 16-fold increase in neutralizing activity against a pseudovirus, compared to S protein group. Additionally, S-NPs-cGAMP induces even higher levels of neutralizing antibodies. Remarkably, the vaccine also triggers a robust humoral immune response, as evidenced by a notable elevation in virus-specific IgG and IgM antibodies. Furthermore, after 42 days of immunization, there is an observed increase in specific immune cell populations in the spleen. CD3+ CD4+ and CD3+ CD8+ T lymphocytes, as well as B220+ CD19+ and CD3- CD49b+ NK lymphocytes, show an upward trend, indicating a positive cellular immune response. Moreover, the S-NPs-cGAMP demonstrates promising results against the Delta strain and exhibits good cross-neutralization potential against other variants. These findings suggest that pDMDAAC NPs is potential adjuvant and could serve as a versatile platform for future vaccine development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a adjuvant | |
| 650 | 4 | |a polydimethyl diallyl ammonium chloride | |
| 650 | 4 | |a subunit vaccine | |
| 700 | 1 | |a Ouyang, Chengcheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Shuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Qiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Weilu |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Baochao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jinzhu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Mi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jizong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Bin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advanced healthcare materials |d 2012 |g (2024) vom: 04. März, Seite e2304575 |w (DE-627)NLM218710070 |x 2192-2659 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:04 |g month:03 |g pages:e2304575 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/adhm.202304575 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 04 |c 03 |h e2304575 | ||